argenex (NASDAQ:ARGX) Price Target Raised to $930.00

argenex (NASDAQ:ARGX) had its price target raised by Piper Sandler from $820.00 to $930.00 in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other brokerages also recently weighed in on ARGX. Wells Fargo & Company boosted their target price on shares of argenex from $741.00 to $756.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Deutsche Bank Aktiengesellschaft downgraded shares of argenex from a “buy” rating to a “hold” rating in a report on Thursday, September 11th. HC Wainwright upped their price objective on shares of argenex from $774.00 to $915.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Stifel Nicolaus set a $882.00 target price on shares of argenex in a research note on Thursday, September 18th. Finally, Bank of America boosted their price target on argenex from $880.00 to $887.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and an average price target of $864.68.

argenex Stock Up 2.2%

NASDAQ ARGX opened at $851.02 on Tuesday. argenex has a fifty-two week low of $510.05 and a fifty-two week high of $855.70. The stock has a market cap of $52.40 billion, a price-to-earnings ratio of 36.54, a price-to-earnings-growth ratio of 0.86 and a beta of 0.45. The business has a fifty day moving average of $780.01 and a 200-day moving average of $660.67.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its holdings in argenex by 14.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock valued at $99,886,000 after purchasing an additional 21,805 shares in the last quarter. Amundi grew its stake in shares of argenex by 8.1% during the first quarter. Amundi now owns 6,351 shares of the company’s stock valued at $3,747,000 after acquiring an additional 478 shares in the last quarter. Voya Investment Management LLC increased its position in shares of argenex by 5.2% during the first quarter. Voya Investment Management LLC now owns 14,905 shares of the company’s stock worth $8,822,000 after acquiring an additional 735 shares during the last quarter. Wealth Management Associates Inc. purchased a new stake in shares of argenex during the first quarter worth about $268,000. Finally, Royal Bank of Canada lifted its stake in shares of argenex by 0.9% in the first quarter. Royal Bank of Canada now owns 38,306 shares of the company’s stock worth $22,673,000 after acquiring an additional 353 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.